RenovoRx Inc (NAS:RNXT)
$ 1.12 -0.2 (-15.38%) Market Cap: 26.83 Mil Enterprise Value: 22.44 Mil PE Ratio: 0 PB Ratio: 10.67 GF Score: 21/100

RenovoRx Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript

Feb 02, 2023 / 09:00PM GMT
Release Date Price: $3.02 (+7.47%)
Shaun Bagai
RenovoRx, Inc. - CEO

Hi. Thank you for joining this talk. My name is Shaun Bagai, CEO of RenovoRx, and I'd love to share our development history and our plans going forward with our new innovative platform. We're a late-stage biopharmaceutical company with an innovative targeted therapy for the treatment of difficult to treat cancers.

These are our forward-looking statements. You can see this in entirety on our website.

And I want to start off by challenging to think about what cancer looks like to you. We've all seen a lot of therapies come through fail for that matter. Some therapies are somewhat successful. When you look at cancer and cancer therapy, what we don't see is life.

This is what we do see. It's really the end stages of these patients. Unfortunately, they're nauseous. They can't eat. They're tired. They can't join families. This is what cancer therapy generally looks like to most of us.

And most of us have been touched by cancer in different ways. And unfortunately, this is the path we've gone down in terms of treatment. And yet when we look

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot